Prasugrel

Type: Product
Name: Prasugrel
First reported Jul 24 2014 - Updated 21 hours ago - 3 reports

Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel

Related Biotechnology, Pharmaceutical and Healthcare NewsRevised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...Original Article: NEXT ARTICLE More From BioPortfolio ... [Published BioPortfolio - 21 hours ago]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Lilly's Efient receives new NICE recommendation

:06 in Pharmaceutical Company Product News Lilly's anti-platelet therapy Efient has been recommended for a new acute coronary syndrome indication by the National Institute for Health and Care Excellence (NICE). The prasugrel-based treatment has been endorsed ... [Published Zenopa - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

NICE recommends drugs for blood clots and constipation

UK healthcare guidance body NICE has recommended drugs targeting blood clots and constipation.It has reviewed its 2009 guidance on prasugrel (Efient, Eli Lilly and Co) and now recommends the drug in combination with aspirin for preventing blood clot. ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Lilly’s Efient and Sucampo's Amitiza win NICE backing

On the same day that were recommended for NHS use in England and Wales, the National Institute for Health and Care Excellence (NICE) backed new treatment options for constipation and blood clot.NICE, which provides healthcare recommendations to the NHS, ... [Published PMLive - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 3 reports

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has reviewed and updated its guidance on Efient (prasugrel), produced by US drug major Eli Lilly (NYSE: LLY).The new guidance recommends the drug in combination ... [Published Pharma Letter - Jul 23 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 2 reports

Reply The Importance of Genotype Variation Beyond Different Antiplatelet Therapy in Nonresponder Patients

We thank Drs. Sardella and Calcagno for their interest in our paper (1) . Following their prior publication (2) , they emphasize the importance of genotyping for the CYP2C19*2 allele to define the pharmacodynamic benefit from prasugrel or double-dose ... [Published Journal of the American College of Cardiology - Jul 15 2014]
Entities: Genotype, Patient, Prasugrel
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Choices, Choices: PCI Adjunctive Pharmacotherapy

No Benefit From Prasugrel PretreatmentThomas Cuisset, MD, PhD: Hello. I am Dr. Cuisset, an interventional cardiologist from Marseille, France. I am here at EuroPCR with Roxana Mehran. Roxana, you just came from the Hot Line session. What can you tell ... [Published Theheart.org - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Crystals of prasugrel hydrobromate

The present application discloses crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of ... [Published Free Patents Online - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Court Report

By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Panacea Biotec, Ltd. 1:14-cv-01064; filed June 26, 2014 in the Southern District of Indiana•Plaintiffs: ... [Published Patent Docs - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Top five lessons learned at EuroPCR 2014

EuroPCR 2014 featured a wide variety of important findings in the field of interventional cardiology, with implications for both clinical practice and future guidelines.Topics covered during presentations at the meeting ranged from advances in transcatheter ... [Published Orthopedics Today - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Some prasugrel prescribing runs counter to labeling

Prescribing patterns for the anticoagulant prasugrel suggest that there is ample room for improvement.Prasugrel (Effient, Eli Lilly/Daiichi Sankyo), while effective in decreasing the risk of MI, stroke and cardiovascular death, has warnings about its ... [Published Cardiovascular Business - Jul 02 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Prasugrel or Clopidogrel in ACS: A Head-to-Head Study

Jeannette Y. Wick, RPh, MBA, FASCPA recent study examines the comparative efficacy of prasugrel and clopidogrel in the treatment of patients who underwent percutaneous coronary intervention.Acute coronary syndrome (ACS) is a killer—it’s the leading cause ... [Published Pharmacy Times - Jun 30 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel"
Professor Carole Longson, director of the centre for health technology evaluation at NICE says: "This review assessed the clinical and cost-effectiveness of prasugrel, noting that since the original guidance was published in 2009 NICE has also published guidance on the use of ticagrelor for the same indication, and the price of another drug, clopidogrel, has reduced as generic versions have become available."
Dr Tim Kinnaird, Consultant Cardiologist at University College Cardiff, who acted as an adviser to the NICE appraisal committee said: "This recommendation is very welcome as it offers clinicians a wider choice to protect ACS patients against atherothrombotic events when undergoing PCI. It is important that all suitable treatment options are available so the most appropriate clinical decision to manage patients can be made particularly for higher-risk patients with other co-morbidities, such as diabetes. Having another cost effective option for UA and NSTEMI patients undergoing PCI is particularly relevant to the UK, as this patient population is generally treated poorly compared to STEMI patients undergoing PCI."
...Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: "Taking these factors into consideration, we are now recommending prasugrel as an option for more people with acute coronary syndromes than our previous guidance." Known as Effient in the US, the drug has also been recommended by NICE as an option for people with non-ST-segment-elevation myocardial infarction and...

More Content

All (41) | News (33) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Heart patients in England and Wales offered mor... [Published BioPortfolio - 21 hours ago]
NICE extends recommendation for Efient [Published Pharmafocus - Jul 24 2014]
Heart patients in England and Wales offered mor... [Published Medical News Today - Jul 24 2014]
Lilly's Efient receives new NICE recommendation [Published Zenopa - Jul 24 2014]
NICE recommends drugs for blood clots and const... [Published BioPortfolio - Jul 24 2014]
Lilly’s Efient and Sucampo's Amitiza win NICE b... [Published PMLive - Jul 23 2014]
UK's NICE changes guidance to recommend Eli Lil... [Published Pharma Letter - Jul 23 2014]
Daiichi Sankyo and Eli Lilly and Company: Heart... [Published Business Wire Health News - Jul 23 2014]
Cost watchdog expands NHS use of bloodthinner E... [Published Pharma Times - Jul 23 2014]
Heart patients in England and Wales offered mor... [Published FirstWord Pharma - Jul 23 2014]
Reply The Importance of Genotype Variation Beyo... [Published Journal of the American College of Cardiology - Jul 15 2014]
The Importance of Genotype Variation Beyond Dif... [Published Journal of the American College of Cardiology - Jul 15 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
HEAT-PPCI Questions? More Answers from Dr Rod S... [Published General Medicine eJournal - Jul 10 2014]
Choices, Choices: PCI Adjunctive Pharmacotherapy [Published Theheart.org - Jul 10 2014]
Crystals of prasugrel hydrobromate [Published Free Patents Online - Jul 08 2014]
Court Report - July 2014 #2 [Published JD Supra - Jul 07 2014]
Court Report [Published Patent Docs - Jul 07 2014]
HEAT-PPCI in Print: 'It's Pretty Bloody Detailed' [Published Diabetes Care - Jul 04 2014]
Net earnings of 5 leading Japanese pharma compa... [Published PharmaBiz - Jul 04 2014]
Top five lessons learned at EuroPCR 2014 [Published Orthopedics Today - Jul 03 2014]
Some prasugrel prescribing runs counter to labe... [Published Cardiovascular Business - Jul 02 2014]
Prasugrel or Clopidogrel in ACS: A Head-to-Head... [Published Pharmacy Times - Jun 30 2014]
Prognostic Value of BARC Bleeding Complications... [Published Theheart.org - Jun 24 2014]
Frequency and Practice-Level Variation in Inapp... [Published Journal of the American College of Cardiology - Jun 24 2014]
NICE to expand use of bloodthinner Efient [Published Pharma Times - Jun 23 2014]
Lilly’s Efient tipped for expanded NICE approval [Published Pharmafocus - Jun 20 2014]
UK’s NICE draft guidance recommends Lilly’s Efient [Published Pharma Letter - Jun 20 2014]
Prasugrel Superior to Clopidogrel in Patients W... [Published Medscape - Jun 18 2014]
Prasugrel Superior to Clopidogrel in Patients W... [Published General Medicine eJournal - Jun 18 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Daiichi Sankyo and Eli Lilly and Company: Heart... [Published Business Wire Health News - Jul 23 2014]
GERRARDS CROSS, England--(BUSINESS WIRE)--Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option when compared ...
Court Report [Published Patent Docs - Jul 07 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Panacea Biotec, Ltd. 1:14-cv-01064; filed June 26, 2014 in the Southern District of Indiana•Plaintiffs: ...
Court Report - Part III [Published Patent Docs - Apr 25 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Apotex Corp. et al. 1:14-cv-00586; filed April 16, 2014 in the Southern District of Indiana•Plaintiffs: ...
Top medicine articles for April 2014 [Published Clinical Cases and Images: CasesBlog - Apr 17 2014]
A collection of some interesting medical articles published recently:Noninfluenza Vaccination Rates Among U.S. Adults Remain Low - only 16% for Tdap in 2012 http://buff.ly/NcduqD Adult Tonsillectomy Shown to Be Safe: 30-day mortality rate was low, ...
Acute coronary syndrome - prasugrel with PCI (r... [Published NICE | National Institute for Health and Clinic ... - Apr 01 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.